Monthly research recap
PTSD research: February 2026
What February 2026's 9 new studies found, synthesized from the papers below. All PTSD research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for PTSD, post-traumatic stress disorder, traumatic stress, then ranked by relevance.
Research published in February 2026 on PTSD spans mechanistic reviews, real-world treatment outcomes, and qualitative access studies. A large retrospective cohort found at-home ketamine-assisted therapy associated with large PTSD symptom reductions (44.6% mean decrease, 79.7% response, 60.7% remission), while reviews highlight the importance of sleep-focused interventions and the synergistic neurobiological and relational mechanisms of MDMA-assisted therapy. However, most evidence is observational or qualitative, with small samples and limited long-term follow-up, so conclusions about efficacy remain preliminary.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment 2026 | position paper | Unclear | Argues that SSRIs, psilocybin, and MDMA act on serotonergic circuits but their mechanisms at molecular, cellular, and neural circuit levels are not well understood, limiting therapeutic development. | |
| MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst? 2026 | review | Supports | Proposes a synergistic model where MDMA's therapeutic effects arise from both neurobiological (reduced amygdala reactivity, enhanced neuroplasticity) and interpersonal (therapeutic alliance) mechanisms, creating a window of emotional safety. | |
| Psychological Determinants of Sleep Paralysis: A Contemporary Review of Anxiety, Stress, and Trauma 2026 | review | Supports | Reviews evidence that anxiety, chronic stress, and trauma exposure are strongly associated with increased frequency, severity, and distress in sleep paralysis episodes, supporting a biopsychosocial understanding. | |
| The role of sleep disturbances in the maintenance of PTSD symptoms: a literature review 2026 | literature review | Supports | Reviews evidence that sleep disturbances are bidirectionally linked to PTSD symptoms and that sleep-focused interventions improve both sleep problems and core PTSD symptoms. | |
| At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis 2026 | retrospective cohort study | 374 | Supports | At-home ketamine-assisted therapy was associated with large reductions in PTSD symptoms, with 79.7% showing clinical response and 60.7% achieving remission after six sessions. |
| Lifetime MDMA use and associations with meaning in life in the context of childhood trauma 2026 | cross-sectional survey | 807 | Mixed | Lifetime MDMA use was not significantly associated with meaning in life overall, but a significant interaction showed higher meaning in life among those with childhood trauma. |
| Barriers and Access to Care for Firefighters with Post-Traumatic Stress Disorder Seeking Ketamine Assisted Therapy: a qualitative study. 2026 | qualitative study | 6 | Unclear | Interviews revealed four major themes: feeling stuck and at a breaking point, stigma about PTSD and ketamine, need for self-advocacy, and substantial financial and logistical barriers to accessing ketamine-assisted therapy. |
| Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis. 2026 | qualitative study | 21 | Supports | Interviews highlighted the importance of expectation management, comprehensive screening, consent, safeguard measures, therapeutic alliance, integration of care, and training of healthcare providers for MDMA-assisted psychotherapy. |
| Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study. 2026 | randomized controlled trial | 36 | Supports | Low-dose oral THC (5 mg or 10 mg) prior to extinction learning affected brain indices of fear learning and memory both acutely and one week after administration, with dose-dependent effects on prefrontal and hippocampal activation. |
Points of agreement
- MDMA-assisted therapy is considered promising for PTSD, with mechanisms involving both neurobiological and relational factors.
- Sleep disturbances are bidirectionally linked to PTSD and sleep-focused interventions improve PTSD symptoms.
- Ketamine-assisted therapy shows large symptom reductions in real-world settings, though access barriers exist.
- Psychedelic and related treatments require careful patient selection, expectation management, and therapeutic support.
Conflicts
- The position paper notes limited mechanistic understanding of SSRIs, psilocybin, and MDMA, while the MDMA review proposes a synergistic model with evidence from human and rodent studies.
- The cross-sectional survey found no overall association between MDMA use and meaning in life, but a positive association in those with childhood trauma, suggesting context-dependent effects.
Gaps
- Long-term durability of treatment effects is not established in most studies.
- Most evidence is observational or qualitative; randomized controlled trials are limited.
- Real-world studies lack blinding and control groups.
- Mechanistic understanding of psychedelic and serotonergic treatments remains incomplete.
- Access barriers and stigma are understudied in larger populations.
- Dose-response relationships for THC and other agents need further investigation.